Search
capreomycin (Capastat)
Tradename: Capastat sulfate.
Indications:
- treatment of tuberculosis in conjunction with at least one other anti-tuberculous agent
Contraindications: hypersensitivity to capreomycin Warnings:
1) use with caution in patients with renal insufficiency
2) use with caution in patients with hearing impairment
Dosage:
1) 15 mg/kg/day up to 1 g/day for 60-120 days, then
2) 15 mg/kg 2-3 times/week
Injection: 100 mg/mL. 10 mL.
Dosage adjustment in renal failure:
- consult manufacturer's guidelines
Pharmacokinetics:
1) 1/2 life: 4-6 hours with normal renal function
2) elminated unchanged in the urine
Monitor:
- renal function tests
- audiometry [2]
Adverse effects:
1) common (> 10%)
- ototoxicity (auditory) (11%)
- nephrotoxicity (36%)
2) less common (1-10%)
- eosinophilia
3) uncommon (< 1%)
- vertigo, fever, rash, leukocytosis, thrombocytopenia, pain, induration, bleeding at injection site, tinnitus
Drug interactions:
1) increased toxicity when concurrently administered with other nephrotoxic or ototoxic agents:
a) streptomycin
b) vancomycin
c) aminoglycosides
2) increased effect or duration of non-depolarizing neuromuscular blocking agents
Test interactions:
1) hypokalemia
2) increased BUN
3) leukocytosis
4) thrombocytopenia
Interactions
drug interactions
General
anti-tuberculous agent
Properties
MISC-INFO: elimination route KIDNEY
pregnancy-category ?
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
- Department of Veterans Affairs, VA National Formulary